Post-marketing surveillance of Euhypnos (temazepam): a new hypnotic.
A post-marketing surveillance study of Euhypnos (temazepam), a new short-acting benzodiazepine hypnotic. A total of 12,350 patients requiring a sleep inducer were treated for up to 3 months with doses of 10-30 mg at night. After 2 weeks 80% of First Reports (FRs) rated Euhypnos effective and at 3 months this had risen to 92% of 3062 Second Reports (SRs). Hangover was reported in 7% of FRs and 2% of SRs but in general the drug was well tolerated with adverse reactions consisting mainly of morning nausea, headache, drowsiness and vivid dreaming. Eighty-seven per cent of FRs and 93% of SRs were 'Clean' reporting no hangover, adverse reaction or event of any kind.
D014151:Anti-Anxiety Agents / Q000009:adverse effects*; D004064:Digestive System / Q000187:drug effects; D004325:Dreams / Q000187:drug effects; D006261:Headache / Q000139:chemically induced; D006801:Humans; D012894:Sleep Stages / Q000187:drug effects; D012893:Sleep Wake Disorders / Q000188:drug therapy*; D013693:Temazepam / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use
D014151:Anti-Anxiety Agents; D013693:Temazepam